GSK Selects Genedata Biologics as Antibody Discovery Platform - - BioPharm International

ADVERTISEMENT

GSK Selects Genedata Biologics as Antibody Discovery Platform



Genedata, a provider of software solutions for drug discovery and life science research, reported that Biopharm R&D at GlaxoSmithKline (GSK) has selected Genedata Biologics as a R&D data management and workflow-support platform. The Genedata Biologics platform will support multiple GSK Biopharm R&D groups including lead identification and screening, protein optimization and engineering, and protein production.

The system can record, manage, and process data from GSK's antibody discovery platforms such as phage and yeast display, hybridoma, and other technologies. Genedata reports that the system can help to improve data quality, improve efficiency through upload and export of instrument data, and increase experimental throughput. Genedata and GSK will work together to support new discovery technologies and next-generation antibody formats.

Source: Genedata

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines

Click here